AU2003276125B2 - Chemical process - Google Patents

Chemical process Download PDF

Info

Publication number
AU2003276125B2
AU2003276125B2 AU2003276125A AU2003276125A AU2003276125B2 AU 2003276125 B2 AU2003276125 B2 AU 2003276125B2 AU 2003276125 A AU2003276125 A AU 2003276125A AU 2003276125 A AU2003276125 A AU 2003276125A AU 2003276125 B2 AU2003276125 B2 AU 2003276125B2
Authority
AU
Australia
Prior art keywords
formula
compound
alkyl
hydrogen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003276125A
Other languages
English (en)
Other versions
AU2003276125A1 (en
Inventor
Amogh Boloor
Mui Cheung
Jeffrey Alan Stafford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2003276125A1 publication Critical patent/AU2003276125A1/en
Application granted granted Critical
Publication of AU2003276125B2 publication Critical patent/AU2003276125B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AU2003276125A 2002-06-17 2003-06-17 Chemical process Ceased AU2003276125B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38934902P 2002-06-17 2002-06-17
US60/389,349 2002-06-17
PCT/US2003/019211 WO2003106416A2 (en) 2002-06-17 2003-06-17 Chemical process

Publications (2)

Publication Number Publication Date
AU2003276125A1 AU2003276125A1 (en) 2003-12-31
AU2003276125B2 true AU2003276125B2 (en) 2007-05-17

Family

ID=29736629

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003276125A Ceased AU2003276125B2 (en) 2002-06-17 2003-06-17 Chemical process

Country Status (10)

Country Link
US (1) US20060252943A1 (ja)
EP (1) EP1515955A4 (ja)
JP (1) JP2005529954A (ja)
CN (1) CN1688553A (ja)
AU (1) AU2003276125B2 (ja)
CA (1) CA2489648A1 (ja)
IL (1) IL165286A0 (ja)
MX (1) MXPA04012860A (ja)
PL (1) PL374963A1 (ja)
WO (1) WO2003106416A2 (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN1894234A (zh) 2003-03-25 2007-01-10 武田药品工业株式会社 二肽基肽酶抑制剂
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
MXPA06001601A (es) 2003-08-13 2006-08-25 Takeda Pharmaceutical Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
EP1659155B1 (en) 2003-08-25 2016-11-16 Kaneka Corporation Curing composition with improved heat resistance
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
WO2006020564A1 (en) * 2004-08-09 2006-02-23 Smithkline Beecham Corporation Pyrimidin derivatives for the treatment of multiple myeloma
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
MX2008006379A (es) * 2005-11-29 2009-03-03 Smithkline Beecham Corp Metodo de tratamiento.
DE602006020611D1 (de) 2005-11-29 2011-04-21 Glaxosmithkline Llc Krebsbehandlungsverfahren
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2008128231A1 (en) 2007-04-16 2008-10-23 Hutchison Medipharma Enterprises Limited Pyrimidine derivatives
KR20170051521A (ko) 2008-04-16 2017-05-11 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
WO2011050159A1 (en) * 2009-10-23 2011-04-28 Glaxo Wellcome Manufacturing Pte Ltd Compositions and processes
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
EP2635557A2 (en) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US20130317029A1 (en) 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
US8846928B2 (en) 2010-11-01 2014-09-30 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as Syk modulators
WO2012073254A1 (en) * 2010-11-29 2012-06-07 Hetero Research Foundation A process for the preparation of pazopanib using novel intermediate
CN102060848B (zh) * 2010-12-09 2013-09-18 天津药物研究院 芳香胺取代的嘧啶衍生物的制备及用途
IN2014CN04065A (ja) 2011-11-23 2015-09-04 Portola Pharm Inc
CN103319410B (zh) * 2012-03-22 2016-04-06 天津药物研究院 一种吲唑化合物的合成方法
CN103373963B (zh) * 2012-04-28 2015-07-08 上海医药工业研究院 盐酸帕唑帕尼的中间体及其制备方法
CN103373989B (zh) * 2012-04-28 2016-04-13 上海医药工业研究院 盐酸帕唑帕尼的中间体的制备方法
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
WO2014097152A1 (en) * 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of pazopanib or salts thereof
EP2935250B1 (en) 2012-12-17 2018-03-28 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
CN103232443B (zh) * 2013-02-01 2014-12-10 天津药物研究院 一种吲唑衍生物的晶型及其制备和用途
CN103450085B (zh) * 2013-08-15 2015-11-18 凯莱英医药集团（天津）股份有限公司 一种盐酸帕唑帕尼关键中间体的制备方法
WO2015068175A2 (en) 2013-11-05 2015-05-14 Laurus Labs Private Limited An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CN106565688B (zh) * 2016-11-11 2018-08-31 重庆医科大学 帕唑帕尼二聚体及其制备方法和用途
CN110028495B (zh) * 2019-05-24 2019-12-03 济南爱思医药科技有限公司 帕唑帕尼盐酸盐的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US20020052386A1 (en) * 2000-02-17 2002-05-02 Armistead David M. Kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
JP2003511378A (ja) * 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
JP3711443B2 (ja) * 2000-10-25 2005-11-02 セイコーエプソン株式会社 インクジェット式記録装置
ATE430742T1 (de) * 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US20020052386A1 (en) * 2000-02-17 2002-05-02 Armistead David M. Kinase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Auwers et al., BERICHTE DER DEUTSCHEN CHEMISCHEN *
Benchidmi et al., J. HET. CHEM., 1979, 16: 1599-1603 *
GESELLSCHAFT, 1920, 53/II:1211-1232 *
Kametani et al., J. HET. CHEM., 1977, 14: 1175-1182 *
Scawan et al., J. HET. CHEM., 1983, 20: 1351-1353 *

Also Published As

Publication number Publication date
PL374963A1 (en) 2005-11-14
US20060252943A1 (en) 2006-11-09
JP2005529954A (ja) 2005-10-06
IL165286A0 (en) 2005-12-18
CA2489648A1 (en) 2003-12-24
AU2003276125A1 (en) 2003-12-31
WO2003106416A2 (en) 2003-12-24
WO2003106416A3 (en) 2004-05-06
EP1515955A2 (en) 2005-03-23
CN1688553A (zh) 2005-10-26
EP1515955A4 (en) 2006-05-03
MXPA04012860A (es) 2005-09-20

Similar Documents

Publication Publication Date Title
AU2003276125B2 (en) Chemical process
EP1343782B1 (en) Pyrimidineamines as angiogenesis modulators
US7459455B2 (en) Pyrimidine compounds
AU2002246723A1 (en) Pyrimidineamines as angiogenesis modulators
EP1487824A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
EP1341771A2 (en) Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
WO2003051886A1 (en) Pyrazolopyridazine derivatives
WO2004112714A2 (en) Chemical compounds

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE NAME OF THE INVENTOR STAFFORD, JEFFREY ALAN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired